A  ||| S:0 E:2 ||| DT
glimpse  ||| S:2 E:10 ||| NN
into  ||| S:10 E:15 ||| IN
the  ||| S:15 E:19 ||| DT
future ||| S:19 E:25 ||| NN
:  ||| S:25 E:27 ||| :
recombinant  ||| S:27 E:39 ||| JJ
proteins  ||| S:39 E:48 ||| NNS
and  ||| S:48 E:52 ||| CC
small  ||| S:52 E:58 ||| JJ
molecules  ||| S:58 E:68 ||| NNS
for  ||| S:68 E:72 ||| IN
targeted  ||| S:72 E:81 ||| JJ
therapies  ||| S:81 E:91 ||| NNS
in  ||| S:91 E:94 ||| IN
rheumatic  ||| S:94 E:104 ||| JJ
diseases  ||| S:104 E:113 ||| NNS
Whether  ||| S:113 E:121 ||| IN
the  ||| S:121 E:125 ||| DT
differences  ||| S:125 E:137 ||| NNS
in  ||| S:137 E:140 ||| IN
the  ||| S:140 E:144 ||| DT
clinical  ||| S:144 E:153 ||| JJ
picture  ||| S:153 E:161 ||| NN
and  ||| S:161 E:165 ||| CC
in  ||| S:165 E:168 ||| IN
the  ||| S:168 E:172 ||| DT
pathogenesis  ||| S:172 E:185 ||| NN
between  ||| S:185 E:193 ||| IN
rheumatoid  ||| S:193 E:204 ||| JJ
arthritis  ||| S:204 E:214 ||| NN
( ||| S:214 E:215 ||| -LRB-
RA ||| S:215 E:217 ||| NNP
)  ||| S:217 E:219 ||| -RRB-
and  ||| S:219 E:223 ||| CC
ankylosing  ||| S:223 E:234 ||| JJ
spondylitis  ||| S:234 E:246 ||| NNS
( ||| S:246 E:247 ||| -LRB-
AS ||| S:247 E:249 ||| NNP
)  ||| S:249 E:251 ||| -RRB-
will  ||| S:251 E:256 ||| MD
lead  ||| S:256 E:261 ||| VB
to  ||| S:261 E:264 ||| TO
different  ||| S:264 E:274 ||| JJ
therapeutic  ||| S:274 E:286 ||| JJ
approaches  ||| S:286 E:297 ||| NNS
is  ||| S:297 E:300 ||| VBZ
unclear  ||| S:300 E:308 ||| JJ
at  ||| S:308 E:311 ||| IN
present ||| S:311 E:318 ||| JJ
.  ||| S:318 E:320 ||| .
Since  ||| S:320 E:326 ||| IN
anti-TNF-alpha  ||| S:326 E:341 ||| JJ
agents  ||| S:341 E:348 ||| NNS
and  ||| S:348 E:352 ||| CC
other  ||| S:352 E:358 ||| JJ
biologics  ||| S:358 E:368 ||| NNS
are  ||| S:368 E:372 ||| VBP
not  ||| S:372 E:376 ||| RB
efficacious  ||| S:376 E:388 ||| VBN
in  ||| S:388 E:391 ||| IN
all  ||| S:391 E:395 ||| DT
patients  ||| S:395 E:404 ||| NNS
new  ||| S:404 E:408 ||| JJ
developments  ||| S:408 E:421 ||| NNS
are  ||| S:421 E:425 ||| VBP
clearly  ||| S:425 E:433 ||| RB
needed ||| S:433 E:439 ||| VBN
.  ||| S:439 E:441 ||| .
